

# Transforming Gynaecological Cancer Care Through Immunotherapy



6 May 2026  
Wednesday



6.55 pm - 8.30 pm



Conrad Singapore Orchard  
Cuscaden Room, Level 2  
1 Cuscaden Rd, Singapore 249715




## Objectives

- Review the current therapeutic management of cervical cancer and ovarian cancer
- Evaluate current evidence of immunotherapy in the management of cervical and ovarian cancer
- Discuss the clinical management of cervical and ovarian cancer using patient case-based learning

## Agenda

| Time    | Program  |
|---------|--|
| 6.55 pm | Welcome and Introduction   |
| 7.00 pm | Transforming Gynaecological Cancer Care Through Immunotherapy<br><i>Prof Charles Leath</i>   |
| 7.45 pm | <b>Patient Case Discussion #1 Locally Advanced Cervical Cancer</b><br><i>Case presenter: Dr Jack Chan</i><br><i>Panel discussion: Prof Charles Leath, Dr Jack Chan, Dr. Lim Sheow Lei</i>          |
| 8.00 pm | <b>Patient Case Discussion #2 Recurrent/Metastatic Cervical Cancer</b><br><i>Case presenter: Dr. Lim Sheow Lei</i><br><i>Panel discussion: Prof Charles Leath, Dr Jack Chan, Dr. Lim Sheow Lei</i> |
| 8.15 pm | <b>Patient Case Discussion #3 Ovarian Cancer</b><br><i>Case presenter: Prof Charles Leath</i><br><i>Panel discussion: Prof Charles Leath, Dr Jack Chan, Dr. Lim Sheow Lei</i>                      |
| 8.30 pm | End  |

## Speakers



### Prof Charles A. Leath III

MD, MSPH, FACS, FACOG

University of Alabama at Birmingham  
Director, Division of Gynecologic Oncology  
Professor of Obstetrics and Gynecology  
Heersink School of Medicine, University of Alabama at Birmingham  
O'Neal Comprehensive Cancer Center

Dr. Leath is the Ellen Gregg Shook Culverhouse Chair in Gynecologic Oncology and Division Director at the University of Alabama at Birmingham where he completed both residency in Obstetrics and Gynecology and fellowship in Gynecologic Oncology. Dr. Leath is the Chair of the NRG Oncology Cervical & Vulvar Cancer Committee and is the National Principal Investigator for NRG clinical trial GY-006 evaluating the addition of triapine to standard chemoradiation for locally advanced cervical cancer. Dr. Leath is board certified in both Obstetrics & Gynecology and Gynecologic Oncology and holds a Masters of Science in Public Health (MSPH) degree from the University of Alabama School of Public Health. He is the institutional principal investigator for the Lead Academic Participating Site (LAPS) grant as part of the National Cancer Institutes' National Clinical Trial Network, the Chair of the O'Neal Comprehensive Cancer Center Protocol Review and Monitoring Committee and is an investigator on the combined Johns Hopkins-UAB Cervical Cancer SPORE. Dr. Leath is actively involved in clinical research in the management of endometrial, cervical, and ovarian cancers, as well as clinical trials for all aspects of gynecologic cancer, and is an author or co-author of over 185 peer-reviewed publications.



### Clin Asst Prof Chan Junjie Jack

MBBS, MRCP (UK), M Med  
(Internal Medicine), FAMS

Senior Consultant, National  
Cancer Centre Singapore



### Dr Lim Sheow Lei

MBBS (Australia, Honours),  
MRCP (United Kingdom),  
MD (United Kingdom)

Senior Consultant Medical  
Oncologist, OncoCare  
Cancer Centre

FOR HEALTHCARE PROFESSIONALS ONLY.  
THIS INVITATION IS ONLY INTENDED FOR THE NAMED RECIPIENT.  
DO NOT SHARE THIS INVITE.

Supported by



Sponsored by



MSD Pharma (Singapore) Pte Ltd.

2 Central Boulevard, IOI Central Boulevard Towers, West Tower  
#39-01, Singapore 018916

Tel: +65 6807 1000 [www.msd-singapore.com](http://www.msd-singapore.com)

Copyright © 2026 Merck & Co., Inc., Rahway, NJ, USA, and its  
affiliates. All rights reserved.